These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37901233)

  • 1. Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report.
    Zheng Y; Xue YY; Zhao YQ; Chen Y; Li ZP
    Front Immunol; 2023; 14():1254812. PubMed ID: 37901233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review.
    Qi X; Guo J; Zhou X; Sun L; Lin J; Huang Z; Chen H; Lin L
    Heliyon; 2022 Sep; 8(9):e10581. PubMed ID: 36185140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report.
    Fan S; He L; Sang D
    Oncol Lett; 2023 Aug; 26(2):359. PubMed ID: 37545624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy combined with immunotherapy in primary female urethral squamous cell carcinoma: a case report.
    Bai H; Han H; Wang F; Shi H
    J Int Med Res; 2022 Oct; 50(10):3000605221132418. PubMed ID: 36281031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation.
    Huang L; Wang R; Xie K; Zhang J; Tao F; Pi C; Feng Y; Gu H; Fang J
    Breast Cancer Res Treat; 2022 Jan; 191(1):51-61. PubMed ID: 34657203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disitamab Vedotin: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(16):1929-1935. PubMed ID: 34661865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy.
    Shi F; Liu Y; Zhou X; Shen P; Xue R; Zhang M
    Drug Deliv; 2022 Dec; 29(1):1335-1344. PubMed ID: 35506447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center's real-world study.
    Wei Y; Zhang R; Yu C; Hong Z; Lin L; Li T; Chen J
    Front Pharmacol; 2023; 14():1230395. PubMed ID: 37645442
    [No Abstract]   [Full Text] [Related]  

  • 9. HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study.
    Chen M; Yao K; Cao M; Liu H; Xue C; Qin T; Meng L; Zheng Z; Qin Z; Zhou F; Liu Z; Shi Y; An X
    Cancer Immunol Immunother; 2023 Jul; 72(7):2309-2318. PubMed ID: 36897337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical safety profile of disitamab vedotin：a novel anti-HER2 antibody conjugated with MMAE.
    Jiang J; Li S; Shan X; Wang L; Ma J; Huang M; Dong L; Chen F
    Toxicol Lett; 2020 May; 324():30-37. PubMed ID: 31877330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report.
    Wu Q; He L; Luo J; Jin W; Xu Y; Wang C
    Oncol Lett; 2022 Oct; 24(4):339. PubMed ID: 36039062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report.
    Qu F; Liu Q; Lu R; Li W
    Front Oncol; 2023; 13():1245701. PubMed ID: 37711199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disitamab vedotin, a novel HER2-directed antibody-drug conjugate in gastric cancer and other solid tumors.
    Hu Y; Zhu Y; Wei X; Tang C; Zhang W
    Drugs Today (Barc); 2022 Oct; 58(10):491-507. PubMed ID: 36305543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
    Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
    Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
    Bednova O; Leyton JV
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Disitamab Vedotin in Treating HER2 2+/FISH- Gastric Cancer.
    Dai L; Jin X; Wang L; Wang H; Yan Z; Wang G; Liang B; Huang F; Luo Y; Chen T; Wang Q
    Onco Targets Ther; 2022; 15():267-275. PubMed ID: 35321517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
    Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
    Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
    Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
    BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.